keyword
MENU ▼
Read by QxMD icon Read
search

rudolph navari

keyword
https://www.readbyqxmd.com/read/27815710/2016-updated-mascc-esmo-consensus-recommendations-prevention-of-nausea-and-vomiting-following-multiple-day-chemotherapy-high-dose-chemotherapy-and-breakthrough-nausea-and-vomiting
#1
Lawrence H Einhorn, Bernardo Rapoport, Rudolph M Navari, Jørn Herrstedt, Mary J Brames
PURPOSE: This review summarizes the recommendations for the prophylaxis of acute and delayed nausea and vomiting induced by multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting as agreed at the MASCC/ESMO Antiemetic Guidelines update meeting in Copenhagen in June 2015. METHODS: A systematic literature search using PubMed from January 01, 2009 through January 06, 2015 with a restriction to papers in English was conducted. RESULTS: There were three phase III randomized trials in patients undergoing high-dose chemotherapy and stem cell transplant and eight single arm non-randomized clinical studies (single in patients undergoing transplantation and one in patients receiving multiple-day chemotherapy treatment)...
January 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27557833/rolapitant-improves-quality-of-life-of-patients-receiving-highly-or-moderately-emetogenic-chemotherapy
#2
Martin Chasen, Laszlo Urban, Ian Schnadig, Bernardo Rapoport, Dan Powers, Sujata Arora, Rudolph Navari, Lee Schwartzberg, Cesare Gridelli
PURPOSE: Addition of rolapitant to standard antiemetic therapy improved protection against chemotherapy-induced nausea and vomiting (CINV) in phase 3 trials of patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). Here, we assessed the impact of CINV on the daily lives of patients receiving HEC or MEC using the Functional Living Index-Emesis (FLIE). METHODS: In three double-blind phase 3 studies, patients receiving HEC or MEC were randomized 1:1 to receive oral rolapitant 180 mg or placebo prior to chemotherapy plus 5-hydroxytryptamine type 3 receptor antagonist and dexamethasone therapy...
January 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27443154/2016-updated-mascc-esmo-consensus-recommendations-prevention-of-nausea-and-vomiting-following-high-emetic-risk-chemotherapy
#3
Jørn Herrstedt, Fausto Roila, David Warr, Luigi Celio, Rudolph M Navari, Paul J Hesketh, Alexandre Chan, Matti S Aapro
PURPOSE: This review summarizes the recommendations for the prophylaxis of nausea and vomiting in adults receiving highly emetogenic chemotherapy (HEC) which includes cisplatin, mechlorethamine, streptozocin, cyclophosphamide >1500 mg/m(2), carmustine, dacarbazine, and the combination of an anthracycline and cyclophosphamide (AC) administered to women with breast cancer, as agreed at the MASCC/ESMO Antiemetic Guidelines Update meeting in Copenhagen in June 2015. METHODS: A systematic review of the literature using PubMed and the Cochrane Database from 2009 to June 2015 was performed...
January 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27410922/olanzapine-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting
#4
RANDOMIZED CONTROLLED TRIAL
Rudolph M Navari, Rui Qin, Kathryn J Ruddy, Heshan Liu, Steven F Powell, Madhuri Bajaj, Leah Dietrich, David Biggs, Jacqueline M Lafky, Charles L Loprinzi
BACKGROUND: We examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy. METHODS: In a randomized, double-blind, phase 3 trial, we compared olanzapine with placebo, in combination with dexamethasone, aprepitant or fosaprepitant, and a 5-hydroxytryptamine type 3-receptor antagonist, in patients with no previous chemotherapy who were receiving cisplatin (≥70 mg per square meter of body-surface area) or cyclophosphamide-doxorubicin...
July 14, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27152512/olanzapine-versus-fosaprepitant-for-the-prevention-of-concurrent-chemotherapy-radiotherapy-induced-nausea-and-vomiting
#5
Rudolph M Navari, Cindy K Nagy, Jennifer Le-Rademacher, Charles L Loprinzi
BACKGROUND: Concurrent chemotherapy radiation therapy may result in significant nausea and vomiting. There have been few studies reporting effective interventions for preventing treatment-related nausea and vomiting. OBJECTIVE: To compare olanzapine with fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent highly emetogenic chemotherapy (HEC) and radiotherapy for locally advanced head and neck or esophageal cancer. METHODS: 120 chemotherapy and radiotherapy naïve patients with head and neck cancer who were receiving concurrent local radiation and cisplatin were randomized to receive either olanzapine or fosaprepitant in combination with palonosetron and dexamethasone for the prevention of chemotherapy- and radiation-induced nausea and vomiting...
April 2016: Journal of Community and Supportive Oncology
https://www.readbyqxmd.com/read/27050207/antiemetic-prophylaxis-for-chemotherapy-induced-nausea-and-vomiting
#6
REVIEW
Rudolph M Navari, Matti Aapro
Chemotherapy-induced nausea and vomiting (chemotherapy-induced emesis) is a common treatment-related side effect that has a detrimental effect on the quality of life of patients with cancer and may lead to dose reductions in or discontinuation of chemotherapy. The development of new antiemetic..
April 7, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/26851398/efficacy-and-safety-of-rolapitant-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-over-multiple-cycles-of-moderately-or-highly-emetogenic-chemotherapy
#7
RANDOMIZED CONTROLLED TRIAL
Bernardo Rapoport, Lee Schwartzberg, Martin Chasen, Dan Powers, Sujata Arora, Rudolph Navari, Ian Schnadig
OBJECTIVE: Rolapitant, a novel neurokinin-1 receptor antagonist (RA), was shown to protect against delayed chemotherapy-induced nausea and vomiting (CINV) during the first cycle of moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC) in randomized, double-blind trials. This analysis explored the efficacy and safety of rolapitant in preventing CINV over multiple cycles of MEC or HEC. PATIENTS AND METHODS: Patients in one phase III MEC, one phase II HEC, and two phase III HEC clinical trials were randomized to receive oral rolapitant (180 mg) or placebo in combination with a 5-hydroxytryptamine type 3 RA and dexamethasone...
April 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/26768437/efficacy-of-olanzapine-for-the-prophylaxis-and-rescue-of-chemotherapy-induced-nausea-and-vomiting-cinv-a-systematic-review-and-meta-analysis
#8
Leonard Chiu, Ronald Chow, Marko Popovic, Rudolph M Navari, Nathan M Shumway, Nicholas Chiu, Henry Lam, Milica Milakovic, Mark Pasetka, Sherlyn Vuong, Edward Chow, Carlo DeAngelis
PURPOSE: Olanzapine is a potent antipsychotic medication that inhibits a wide variety of receptors. It has been used in trials for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV). This study systematically investigates the efficacy of olanzapine in relation to other antiemetics in the prophylaxis and rescue of CINV. METHODS: A literature search of Ovid MEDLINE, EMBASE, and CENTRAL was conducted to identify randomized controlled trials (RCTs) comparing olanzapine to other standard antiemetics for either prevention or rescue...
May 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/26699406/the-safety-of-antiemetic-medications-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting
#9
Rudolph M Navari
INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life and is perceived by patients as a major adverse effect of the treatment. The purpose of the review is to determine the safety and efficacy of current antiemetic agents. AREAS COVERED: Information on antiemetic guideline recommended antiemetics derived from PubMed showed that the first and second generation 5-hydroxytryptamine-3 (5-HT3) receptor antagonists have been safe and effective in the control of acute emesis with a small number of patients experiencing mild headache, diarrhea, or constipation...
2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/26530228/efficacy-and-safety-of-olanzapine-for-the-prophylaxis-of-chemotherapy-induced-nausea-and-vomiting-cinv-as-reported-in-phase-i-and-ii-studies-a-systematic-review
#10
REVIEW
Ronald Chow, Leonard Chiu, Rudolph Navari, Steven Passik, Nicholas Chiu, Marko Popovic, Henry Lam, Mark Pasetka, Edward Chow, Carlo DeAngelis
INTRODUCTION: Olanzapine is an atypical antipsychotic drug that inhibits serotonergic, dopaminergic, alpha-1 adrenergic, histaminic, and muscarinic receptors. Several phase I and II trials have been published documenting the use of olanzapine in controlling chemotherapy-induced nausea and vomiting (CINV). This review aims to summarize all phase I and II trials that reported on olanzapine for the prophylaxis of CINV. METHODS: A literature search was conducted in Ovid MEDLINE from 1946 to July week 1 2015, Embase Classic and Embase from 1947 to 2015 week 28, and the Cochrane Central Register of Controlled Trials up until June 2015...
February 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/26421294/treatment-of-breakthrough-and-refractory-chemotherapy-induced-nausea-and-vomiting
#11
REVIEW
Rudolph M Navari
Despite significant progress in the prevention of chemotherapy-induced nausea and vomiting (CINV) with the introduction of new antiemetic agents, 30-50% of patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC) and guideline directed prophylactic antiemetics develop breakthrough CINV. International guidelines recommend the treatment of breakthrough CINV with an agent from a drug class that was not used in the prophylactic antiemetic regimen and recommend using the breakthrough medication continuously rather than using it on an as needed basis...
2015: BioMed Research International
https://www.readbyqxmd.com/read/26366937/rolapitant-for-the-treatment-of-chemotherapy-induced-nausea-and-vomiting
#12
COMPARATIVE STUDY
Rudolph M Navari
Chemotherapy-induced nausea and vomiting is a significant clinical issue which affects patient's quality of life and treatment decisions. Significant improvements in the control of chemotherapy-induced nausea and vomiting have occurred in the past 15 years with the introduction of new antiemetic agents 5-HT3, receptor antagonists, neurokinin-1 (NK-1) receptor antagonists, and olanzapine. Aprepitant was the first NK-1 receptor antagonist introduced (2003) for the prevention of chemotherapy-induced nausea and vomiting in combination with a 5-HT3 receptor antagonist and dexamethasone...
2015: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/26272769/safety-and-efficacy-of-rolapitant-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-after-administration-of-cisplatin-based-highly-emetogenic-chemotherapy-in-patients-with-cancer-two-randomised-active-controlled-double-blind-phase-3-trials
#13
RANDOMIZED CONTROLLED TRIAL
Bernardo L Rapoport, Martin R Chasen, Cesare Gridelli, Laszlo Urban, Manuel R Modiano, Ian D Schnadig, Allen Poma, Sujata Arora, Vikram Kansra, Lee S Schwartzberg, Rudolph M Navari
BACKGROUND: Highly emetogenic chemotherapy induces emesis in almost all patients in the absence of prophylaxis. Guidelines recommend use of a neurokinin-1 (NK-1) receptor antagonist in conjunction with a 5-HT3 receptor antagonist and corticosteroid in patients receiving highly emetogenic chemotherapy. We aimed to assess rolapitant, an NK-1 receptor antagonist, for prevention of chemotherapy-induced nausea and vomiting in patients with cancer after administration of cisplatin-based highly emetogenic chemotherapy...
September 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26272768/safety-and-efficacy-of-rolapitant-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-after-administration-of-moderately-emetogenic-chemotherapy-or-anthracycline-and-cyclophosphamide-regimens-in-patients-with-cancer-a-randomised-active-controlled-double
#14
RANDOMIZED CONTROLLED TRIAL
Lee S Schwartzberg, Manuel R Modiano, Bernardo L Rapoport, Martin R Chasen, Cesare Gridelli, Laszlo Urban, Allen Poma, Sujata Arora, Rudolph M Navari, Ian D Schnadig
BACKGROUND: Chemotherapy-induced nausea and vomiting is a common side-effect of many antineoplastic regimens and can occur for several days after treatment. We aimed to assess the neurokinin-1 receptor antagonist rolapitant, in combination with a serotonin (5-HT3) receptor antagonist and dexamethasone, for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer after administration of moderately emetogenic chemotherapy or regimens containing an anthracycline and cyclophosphamide...
September 2015: Lancet Oncology
https://www.readbyqxmd.com/read/25855942/clinical-trial-data-in-chemotherapy-induced-nausea-and-vomiting
#15
Rudolph M Navari
No abstract text is available yet for this article.
March 2014: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/25838122/5-ht3-receptors-as-important-mediators-of-nausea-and-vomiting-due-to-chemotherapy
#16
Rudolph M Navari
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles, and patient risk factors significantly influence CINV. The use of a combination of a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, dexamethasone, and a neurokinin-1 (NK-1) receptor antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy. The first generation 5-HT3 receptor antagonists have been very effective in the control of chemotherapy induced emesis in the first 24 h postchemotherapy (acute emesis), but have not been as effective against delayed emesis (24-120 h postchemotherapy)...
October 2015: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/25552904/profile-of-netupitant-palonosetron-nepa-fixed-dose-combination-and-its-potential-in-the-treatment-of-chemotherapy-induced-nausea-and-vomiting-cinv
#17
REVIEW
Rudolph M Navari
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles, and patient risk factors significantly influence CINV. The use of a combination of a 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, dexamethasone, and a neurokinin-1 (NK-1) receptor antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy. Palonosetron, a second generation 5-HT3 receptor antagonist with a different half-life, different binding capacity, and a different mechanism of action than the first generation 5-HT3 receptor antagonists, appears to be the most effective agent in its class...
2015: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/25323946/palonosetron-for-the-treatment-of-chemotherapy-induced-nausea-and-vomiting
#18
REVIEW
Rudolph M Navari
INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles, and patient risk factors significantly influence CINV. The introduction of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists has been a major factor in the improvement of the prevention of chemotherapy-induced acute and delayed emesis. Palonosetron , a second-generation 5-HT3 receptor antagonist with a different half-life, a different binding capacity, and a different mechanism of action than the first-generation 5-HT3 receptor antagonists appears to be the most effective agent in this drug class...
December 2014: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/24874107/clinical-roundtable-monograph-new-data-in-emerging-treatment-options-for-chemotherapy-induced-nausea-and-vomiting
#19
Gary R Morrow, Rudolph M Navari, Hope S Rugo
Chemotherapy-induced nausea and vomiting (CINV) has long been one of the most troublesome adverse effects of chemotherapy, leading to significant detriments in quality of life and functioning, increased economic costs, and, in some cases, the discontinuation of effective cancer therapy. The past 2 decades have witnessed a dramatic increase in the number of effective antiemetic agents, with the introduction of the serotonin (5-hydroxytryptamine [5-HT₃]) receptor antagonists (ondansetron, granisetron, and palonosetron), the neurokinin-1 (NK₁) receptor antagonists (aprepitant and fosaprepitant), and the identification of other agents that have demonstrated efficacy against CINV, including corticosteroids...
March 2014: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/24157985/olanzapine-for-the-prevention-and-treatment-of-chronic-nausea-and-chemotherapy-induced-nausea-and-vomiting
#20
REVIEW
Rudolph M Navari
Olanzapine is an atypical antipsychotic agent of the thiobenzodiazepine class. It blocks multiple neurotransmitter receptors including dopaminergic at D1, D2, D3, D4 brain receptors, serotonergic at 5-HT2a, 5-HT2c, 5-HT3, 5-HT6 receptors, catecholamines at alpha1 adrenergic receptors, acetylcholine at muscarinic receptors, and histamine at H1 receptors. Olanzapine has five times the affinity for 5-HT2 receptors than D2 receptors and has been used to treat schizophrenia and delirium. Olanzapine's activity at multiple receptors, particularly at the D2, 5-HT2c, and 5-HT3 receptors which appear to be involved in nausea and emesis, has prompted its use in the treatment of nausea and vomiting refractory to standard antiemetics...
January 5, 2014: European Journal of Pharmacology
keyword
keyword
100827
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"